Wendt Daniel, Al-Rashid Fadi, Kahlert Philipp, El-Chilali Karim, Demircioglu Ender, Neuhäuser Markus, Liakopoulos Oliver, Sebastian Dohle Daniel, Erbel Raimund, Jakob Heinz, Thielmann Matthias
Department of Thoracic and Cardiovascular Surgery, West-German Heart and Vascular Center Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Department of Cardiology, West-German Heart and Vascular Center Essen, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
J Cardiol. 2015 Oct;66(4):292-7. doi: 10.1016/j.jjcc.2015.04.003. Epub 2015 May 11.
Clinical outcomes were compared among patients with previous cardiac surgery undergoing transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (AVR).
Between 2007 and 2014 a total of 142 consecutive patients with previous cardiac surgery were treated by TAVI either by the transfemoral (n=68) or transapical access (n=74), and 236 patients underwent a surgical redo-AVR. Of these patients, propensity analysis (m:n) matched 62 (group 1, TAVI) and 51 patients (group 2, redo-AVR). A multivariate logistic regression model was constructed. Moreover, mortality was compared between both groups by Cox regression.
Both groups differed significantly (p<0.01) in regard to age and preoperative risk scores (EuroSCORE and STS-Score). Thirty-day mortality was 14.5% (9/62) in group 1 and 5.8% (3/51) in group 2 (p=0.23). Risk-adjusted multivariable analysis revealed only the logistic EuroSCORE to be strongly correlated with 30-day mortality (p=0.01). Multivariate analysis showed no difference in 30-day mortality between both groups (p=0.21). Multivariate Cox regression revealed New York Heart Association functional class (p=0.001), logistic EuroSCORE (p=0.01), and STS-Score (p=0.03) to be strongly associated with overall mortality. Moreover, evaluating overall mortality, Cox regression showed no difference between both groups (p=0.36).
The present study shows that in patients with cardiac reoperation, TAVI comes with similar outcomes when compared to surgical AVR. On the other hand, conventional redo-AVR is still a valuable and safe treatment option.
对曾接受心脏手术的患者进行经导管主动脉瓣植入术(TAVI)或外科主动脉瓣置换术(AVR)后的临床结局进行比较。
2007年至2014年间,共有142例曾接受心脏手术的连续患者接受了TAVI治疗,其中经股动脉途径(n = 68)或经心尖途径(n = 74),另有236例患者接受了再次外科AVR。在这些患者中,倾向分析(m:n)匹配了62例(第1组,TAVI)和51例患者(第2组,再次AVR)。构建了多变量逻辑回归模型。此外,通过Cox回归比较两组的死亡率。
两组在年龄和术前风险评分(欧洲心脏手术风险评估系统和胸外科医师协会评分)方面存在显著差异(p<0.01)。第1组30天死亡率为14.5%(9/62),第2组为5.8%(3/51)(p = 0.23)。风险调整后的多变量分析显示,仅逻辑欧洲心脏手术风险评估系统与30天死亡率密切相关(p = 0.01)。多变量分析显示两组30天死亡率无差异(p = 0.21)。多变量Cox回归显示纽约心脏协会心功能分级(p = 0.001)、逻辑欧洲心脏手术风险评估系统(p = 0.01)和胸外科医师协会评分(p = 0.03)与总体死亡率密切相关。此外,在评估总体死亡率时,Cox回归显示两组之间无差异(p = 0.36)。
本研究表明,在再次心脏手术患者中,与外科AVR相比,TAVI的结局相似。另一方面,传统的再次AVR仍然是一种有价值且安全的治疗选择。